Decreased Enteric Bacterial Composition and Diversity in South American Crohn’s Disease Vary With the Choice of Treatment Strategy and Time Since Diagnosis

• Published in: Journal of Crohn's and colitis 2020-07, Vol.14 (6), p.791-800
• Main Authors: Cruz-Lebrón, Angélica, D’argenio Garcia, Leticia, Talla, Aarthi, Joussef-Piña, Samira, Quiñones-Mateu, Miguel E, Sékaly, Rafick-Pierre, de Carvalho, Karina Inacio Ladislau, Levine, Alan D
• Format: Article
• Language: English
• Subjects: Brazil - epidemiology; Crohn Disease - diagnosis; Crohn Disease - drug therapy; Crohn Disease - epidemiology; Crohn Disease - microbiology; Dysbiosis - chemically induced; Dysbiosis - microbiology; Dysbiosis - physiopathology; Dysbiosis - therapy; Feces - microbiology; Gastrointestinal Microbiome - drug effects; Gastrointestinal Microbiome - genetics; Glucocorticoids - therapeutic use; Humans; Intestinal Mucosa - microbiology; Intestinal Mucosa - pathology; Leukocyte L1 Antigen Complex - analysis; Lipopolysaccharide Receptors - blood; Male; Original; Prevalence; RNA, Ribosomal, 16S - analysis; Severity of Illness Index; Tumor Necrosis Factor Inhibitors - therapeutic use
• ISSN: 1873-9946; 1876-4479
• DOI: 10.1093/ecco-jcc/jjz189

Abstract Background and Aims The symptomology of Crohn’s disease [CD], a chronic inflammatory disease of the digestive tract, correlates poorly with clinical, endoscopic or immunological assessments of disease severity. The prevalence of CD in South America is rising, reflecting changes in socio-economic stability. Many treatment options are available to CD patients, including biological agents and corticosteroids, each of which offers variable efficacy attributed to host genetics and environmental factors associated with alterations in the gut microbiota. Methods Based on 16S rRNA gene sequencing and taxonomic differences, we compared the faecal microbial population of Brazilian patients with CD treated with corticosteroid or anti-tumour necrosis factor [anti-TNF] immunotherapy. Faecal calprotectin and plasma sCD14 levels were quantified as markers for local and systemic inflammation, respectively. Results Anti-TNF treatment led to an increased relative abundance of Proteobacteria and a decreased level of Bacteroidetes. In contrast, corticoid treatment was associated with an increase in the relative abundance of Actinobacteria, which has been linked to inflammation in CD. Disruption of the faecal microbiota was related to decreased bacterial diversity and composition. Moreover, the choice of clinical regimen and time since diagnosis modulate the character of the resulting dysbiosis. Conclusions Enteric microbial populations in CD patients who have been treated are modulated by disease pathogenesis, local inflammatory microenvironment and treatment strategy. The dysbiosis that remains after anti-TNF treatment due to decreased bacterial diversity and composition abates restoration of the microbiota to a healthy state, suggesting that the identification and development of new clinical treatments for CD must include their capacity to normalize the gut microbiota.